Malone, T;
Schӓfer, L;
Simon, N;
Heavey, S;
Cuffe, S;
Finn, S;
Moore, G;
(2020)
Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
Pharmacology & Therapeutics
, 207
, Article 107454. 10.1016/j.pharmthera.2019.107454.
Preview |
Text
1-s2.0-S0163725819302062-main.pdf - Accepted Version Download (1MB) | Preview |
Abstract
PIM kinases are a class of serine/threonine kinases that play a role in several of the hallmarks of cancer including cell cycle progression, metabolism, inflammation and immune evasion. Their constitutively active nature and unique catalytic structure has led them to be an attractive anticancer target through the use of small molecule inhibitors. This review highlights the enhanced activity of PIM kinases in cancer that can be driven by hypoxia in the tumour microenvironment and the important role that aberrant PIM kinase activity plays in resistance mechanisms to chemotherapy, radiotherapy, anti-angiogenic therapies and targeted therapies. We highlight an interaction of PIM kinases with numerous major oncogenic players, including but not limited to, stabilisation of p53, synergism with c-Myc, and notable parallel signalling with PI3K/Akt. We provide a comprehensive overview of PIM kinase's role as an escape mechanism to targeted therapies including PI3K/mTOR inhibitors, MET inhibitors, anti-HER2/EGFR treatments and the immunosuppressant rapamycin, providing a rationale for co-targeting treatment strategies for a more durable patient response. The current status of PIM kinase inhibitors and their use as a combination therapy with other targeted agents, in addition to the development of novel multi-molecularly targeted single therapeutic agents containing a PIM kinase targeting moiety are discussed.
Archive Staff Only
 |
View Item |
